5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
What is actually established about rosuvastatin dosing in Hispanic and Latino patients versus what is extrapolated from pharmacogenomic and cardiometabolic data, with a monitoring framework for clinicians.
A clinical deep-dive into how rosuvastatin (Crestor) performs in Hispanic and Latino patients, covering pharmacogenomics, LDL response differences, CYP2C9 variants, diabetes risk, and evidence-based dosing guidance.
Rosuvastatin (Crestor) pharmacogenomics, dosing considerations, and safety data relevant to Hispanic and Latino patients, with an honest accounting of what is directly studied versus extrapolated.
Evidence-based review of how rosuvastatin safety, pharmacokinetics, and dosing considerations differ for Black and African ancestry patients, including pharmacogenomic factors and clinical trial subgroup data.
South Asian patients metabolize rosuvastatin differently due to ABCG2 and SLCO1B1 polymorphisms, leading to higher plasma exposure at standard doses. Evidence-based dosing considerations and open questions reviewed.